Studies have shown that other immune checkpoints such as TIGIT, LAG-3, and TIM-3 may play a role in promoting tumor immune evasion and exhaustion of virus-specific T cells [31–34], suggesting that combination ICI therapy may need to be explored to effectively treat both cancer and chronic viral infection. The gene discussed is HAVCR2; the disease is cancer.